Related Experiment Videos
Endocrine pancreatic function in growth-retarded fetuses.
C Hubinont1, U Nicolini, N M Fisk
1Institute of Obstetrics and Gynecology, Royal Postgraduate Medical School, London, United Kingdom.
Obstetrics and Gynecology
|April 1, 1991
Summary
Fetal growth restriction is linked to altered glucose metabolism. Elevated fetal glucagon may indicate fetal compromise, offering a better indicator than glucose or insulin levels.
Area of Science:
- Perinatal Medicine
- Endocrinology
- Fetal Physiology
Background:
- Fetal growth restriction (FGR) impacts neonatal outcomes.
- Understanding metabolic adaptations in FGR is crucial for clinical management.
Purpose of the Study:
- To investigate maternal-fetal glucose dynamics and fetal hormonal profiles in FGR.
- To assess the utility of fetal glucose, insulin, and glucagon as indicators of fetal compromise.
Main Methods:
- Measured maternal-fetal glucose gradient, fetal plasma glucose, insulin, and glucagon in 63 fetuses (34 controls, 29 FGR).
- Subdivided FGR group based on umbilical artery end-diastolic frequencies.
Main Results:
- Growth-retarded fetuses exhibited higher maternal-fetal glucose gradients and fetal glucagon, but lower fetal glucose and insulin compared to controls.
- Within the FGR group, fetuses without end-diastolic frequencies had elevated fetal glucagon.
- Fetal glucagon levels correlated with indicators of fetal compromise.
Conclusions:
- Increased fetal glucagon in FGR may represent a compensatory response to hypoglycemia.
- Fetal glucagon appears to be a more sensitive marker of fetal compromise in FGR than fetal glucose or insulin.